PATENT CLAIM ANALYSIS

Application Number: 15885220
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["514", "001100"]

Abstract:
The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.

Claim (Index 49):
The compound according to  claim 45 , wherein AH is a group of formula H-A a -A b - in which A a  is as defined in  claim 45  and A b  is a phenyl-(C 1 -C 2 )alkanediyl group.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 86.0
- Lexical Diversity: 1.625
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15306404', '15306351', '15305157', '14923022', '14292289']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8132121651671086
- 35 USC 102 Novelty (BERT): 0.5877875806899309
- Combined Prediction Score: 0.7906697067193909
- Mean Citation Score: 411.62377999999984
- Max Citation Score: 613.6578
- Similarity Product: 388.2014297248364

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test